UA103032C2 - Селективні антитіла проти гепсидину-25 та їх застосування - Google Patents

Селективні антитіла проти гепсидину-25 та їх застосування

Info

Publication number
UA103032C2
UA103032C2 UAA201101111A UAA201101111A UA103032C2 UA 103032 C2 UA103032 C2 UA 103032C2 UA A201101111 A UAA201101111 A UA A201101111A UA A201101111 A UAA201101111 A UA A201101111A UA 103032 C2 UA103032 C2 UA 103032C2
Authority
UA
Ukraine
Prior art keywords
antibodies
hepcidin
human
useful
selective antibodies
Prior art date
Application number
UAA201101111A
Other languages
English (en)
Russian (ru)
Inventor
Донмайєнн Дон Мун Льюнг
Пен Луань
Їнь Тань
Деррік Райан Уітчер
Піа Пауліїна Якхі
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA103032C2 publication Critical patent/UA103032C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід стосується моноклональних антитіл, які зв'язуються з N-кінцем людського гепсидину-25 і відрізняються тим, що мають високу спорідненість та селективність до згаданого поліпептиду. Антитіла за винаходом є прийнятними для підвищення рівнів заліза у сироватці, кількості ретикулоцитів, кількості еритроцитів, рівнів гемоглобіну та/або гематокриту у людини та для лікування різних розладів у людини, таких як анемія,. Антитіла за цим винаходом є також прийнятними як аналітичні інструменти, наприклад сендвіч-ELISA.
UAA201101111A 2008-08-06 2009-07-29 Селективні антитіла проти гепсидину-25 та їх застосування UA103032C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06
PCT/US2009/052044 WO2010017070A1 (en) 2008-08-06 2009-07-29 Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA103032C2 true UA103032C2 (uk) 2013-09-10

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201101111A UA103032C2 (uk) 2008-08-06 2009-07-29 Селективні антитіла проти гепсидину-25 та їх застосування

Country Status (19)

Country Link
US (1) US8609817B2 (uk)
EP (1) EP2328931B1 (uk)
JP (1) JP5730200B2 (uk)
KR (1) KR101462307B1 (uk)
CN (1) CN102112489B (uk)
AU (1) AU2009279865B2 (uk)
BR (1) BRPI0916624A2 (uk)
CA (1) CA2733497C (uk)
DK (1) DK2328931T3 (uk)
EA (1) EA201170312A1 (uk)
ES (1) ES2432018T3 (uk)
IL (1) IL210643A (uk)
MX (1) MX2011001363A (uk)
NZ (1) NZ590863A (uk)
PL (1) PL2328931T3 (uk)
PT (1) PT2328931E (uk)
UA (1) UA103032C2 (uk)
WO (1) WO2010017070A1 (uk)
ZA (1) ZA201100261B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543630T3 (es) * 2003-04-01 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US9610356B2 (en) 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2968503B1 (en) * 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
WO2016027469A1 (ja) * 2014-08-21 2016-02-25 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US11203753B2 (en) 2015-03-13 2021-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
WO2018063963A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021222875A1 (en) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JPWO2022154121A1 (uk) * 2021-01-18 2022-07-21

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
JP2007518062A (ja) 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
JP5069214B2 (ja) * 2005-03-11 2012-11-07 ヴァーミリオン インコーポレイテッド 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
ES2385772T3 (es) * 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法

Also Published As

Publication number Publication date
AU2009279865A1 (en) 2010-02-11
ES2432018T3 (es) 2013-11-29
PT2328931E (pt) 2013-11-07
DK2328931T3 (da) 2013-09-30
US20110189190A1 (en) 2011-08-04
CN102112489A (zh) 2011-06-29
IL210643A (en) 2015-09-24
EP2328931B1 (en) 2013-08-14
JP5730200B2 (ja) 2015-06-03
US8609817B2 (en) 2013-12-17
MX2011001363A (es) 2011-04-26
CA2733497C (en) 2015-06-02
KR101462307B1 (ko) 2014-11-17
BRPI0916624A2 (pt) 2015-12-01
JP2011530514A (ja) 2011-12-22
EP2328931A1 (en) 2011-06-08
ZA201100261B (en) 2012-06-27
IL210643A0 (en) 2011-03-31
HK1156326A1 (en) 2012-06-08
AU2009279865B2 (en) 2013-10-10
WO2010017070A1 (en) 2010-02-11
CA2733497A1 (en) 2010-02-11
CN102112489B (zh) 2014-05-14
NZ590863A (en) 2012-10-26
KR20110031963A (ko) 2011-03-29
EA201170312A1 (ru) 2012-03-30
PL2328931T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
WO2006118772A3 (en) Fcrn antibodies and uses thereof
GEP20146112B (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof
PH12015501848A1 (en) Binding agents
HK1207655A1 (en) Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2013119966A3 (en) Single-chain antibodies and other heteromultimers
MY174493A (en) Binding agents
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
TW200722437A (en) Anti-TrkB monoclonal antibodies and uses thereof
IL185754A0 (en) Novel anti-plgf antibody
TN2010000213A1 (en) Wise binding antibodies and epitopes
ZA200606516B (en) Antibodies against clostridium difficile toxins and uses thereof
PH12014502419A1 (en) Specific binding proteins and uses thereof
SG196839A1 (en) Antibodies against fcrn and use thereof
WO2006082406A3 (en) Human antibodies and proteins
WO2011041319A8 (en) Specific binding proteins and uses thereof
WO2010014830A3 (en) Peptide therapeutics that bind vegf and methods of use thereof
WO2009140623A3 (en) Anti-psgl-1 antibodies and methods of identification and use
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses